Source: Forbes
The official website of the Kataeb Party leader
Security & Justice
Israel Army Says Hit Over 100 'Terror Targets' in Lebanon in Past Day
The Israeli military on Wednesday said it struck more than 100 "terror targets" in Lebanon over the past day and had "eliminated" two Hezbollah commanders at the weekend.
Wednesday, November 20, 2024
Israeli Strikes Kill Four Lebanese Soldiers in Two Days, Army Reports
Israeli Strikes Kill Four Lebanese Soldiers in Two Days, Army Reports
Wednesday, November 20, 2024
Opinion
Lebanon's Economy—Not Battlefield—May Have the Final Word
Time and again during this most recent war in Lebanon, we hear the phrase, “The battlefield has the final word”. It has become the sole and wholly unsatisfactory refrain of Hezbollah and the so-called 'Axis of Resistance'.
Wednesday, November 20, 2024
Flying Above the Bombs, a Lebanese Airline Becomes an Unlikely National Hero
It used to be like almost any other national carrier, fielding gripes about flight delays, ticket prices and bad food.
Wednesday, November 20, 2024
Sports
Alcaraz Beats Rublev to Open ATP Finals Account
Carlos Alcaraz opened his account at the ATP Finals on Wednesday with an entertaining 6-3, 7-6 (10/8) win over Andrey Rublev which boosted his hopes of reaching the semifinals.
Wednesday, November 13, 2024
Ecuador's Angulo, 22, Dies a Month After Car Crash
Ecuador international Marco Angulo has died at the age of 22 just over a month after being seriously injured in a car crash, his club has announced.
Tuesday, November 12, 2024
Friday 5 July 2024 18:51:51
Drugs Like Ozempic Could Lower Cancer Risks, Study Suggests
A class of diabetes and weight loss drugs that includes Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro could also help protect against a variety of cancers, according to new research published Friday, adding to mounting evidence the injections offer numerous additional health benefits as pressure builds for insurers and public health providers to cover the popular medication in spite of persistent shortages and cost concerns.
KEY FACTS
Glucagon-like peptide receptor agonists, a class of drugs often known as GLP-1s or GLP-1RAs, were associated with a “significant risk reduction” for 10 different cancers when used to treat type 2 diabetes compared to insulin, according to new research published in JAMA Oncology.
The findings come from an analysis of the electronic health records of 1.7 million U.S. patients over 15 years who were prescribed GLP-1RAs, insulins or metformin for type 2 diabetes — all help control blood sugar — between 2005 to 2018, though it did not specify which drugs were examined.
GLP-1 drugs, which mimic the action of a gut hormone and can help control blood sugar, include popular obesity and diabetes treatments like Ozempic and Wegovy (brand names for semaglutide), Mounjaro and Zepbound (or tirzepatide), Victoza and Saxenda (liraglutide) and Trulicity (dulaglutide).
Semaglutide was only authorized for medical use towards the end of the study timeline and tirzepatide was not approved until much later, though findings for some drugs can give an indication for what might happen with closely related drugs.
All of the 13 cancers studied are considered obesity-associated cancers as excess body fat has been linked to a greater risk of developing them and worse prognosis among patients who do.
GLP-1RAs were linked to a greatly reduced risk of developing esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancers, as well as meningioma and multiple myeloma, compared to patients taking insulin.
There was no firm evidence for a lower risk for developing the obesity-associated cancers compared to patients taking metformin for their diabetes, however, though the researchers said there were promising but statistically insignificant indications of a lower risk for gallbladder and colorectal cancer.
SURPRISING FACT
While GLP-1RAs were associated with a decreased risk for most obesity-associated cancers studied compared to other standard diabetes treatments, the researchers said drugs were also associated with a risk of developing some cancers. Compared to patients on metformin, patients taking GLP-1RAs had a higher risk of kidney cancers, the researchers said, though the risk was also lower than patients taking insulin.
There have been no previous reports of kidney cancers associated with using GLP-1s, which are known to have direct effect on kidney function and have been linked to lower rates of kidney disease.
Nevertheless, the researchers said the findings should be followed up for “full evaluation” and suggest the need for continuous monitoring of patients being treated with GLP-1RAs.
There was also no significant reduction in the risk of developing thyroid cancer for patients taking GLP-1RAs compared to insulins, the researchers said.
This finding adds weight to existing research highlighting concerns the drugs are associated with an increased risk of developing thyroid cancer and support warnings on drug packages advising caution among patients with endocrine or thyroid problems.
WHAT WE DON’T KNOW
The study was observational in nature and therefore can only determine relationships, not cause and effect. It’s possible the reduction in risk for obesity-associated cancers comes from the weight loss and diabetes control afforded by such medications, as these are both issues linked to higher risks of cancers, or from some action of the drug itself or another thing entirely.
Given the data available, the researchers said the study doesn’t consider “newer and possibly more effective antidiabetic and weight loss agents,” which could show even more pronounced effects, as well as those with multihormone agonist activities that are increasingly coming to market (tirzepatide, for example, is a multihormone agonist).